NeoGenomics, Inc. (NASDAQ:NEO) insider George Cardoza sold 51,556 shares of NeoGenomics stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $22.82, for a total transaction of $1,176,507.92. Following the transaction, the insider now directly owns 356,387 shares in the company, valued at $8,132,751.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ NEO traded up $0.68 on Friday, hitting $22.69. The stock had a trading volume of 494,000 shares, compared to its average volume of 995,542. The business’s fifty day moving average price is $20.66 and its 200 day moving average price is $22.50. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.24 and a quick ratio of 4.05. NeoGenomics, Inc. has a 52-week low of $11.05 and a 52-week high of $26.89. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of 174.54 and a beta of 0.94.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The business had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. During the same period in the previous year, the company earned $0.05 earnings per share. The business’s revenue for the quarter was up 51.5% on a year-over-year basis. As a group, sell-side analysts anticipate that NeoGenomics, Inc. will post 0.19 EPS for the current year.
NEO has been the topic of several research reports. Raymond James lifted their price objective on shares of NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, July 31st. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Tuesday. BidaskClub raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of NeoGenomics in a report on Tuesday, October 29th. Finally, Needham & Company LLC lifted their price target on shares of NeoGenomics from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $24.86.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEO. NEXT Financial Group Inc grew its holdings in shares of NeoGenomics by 200.0% during the second quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock valued at $59,000 after buying an additional 1,800 shares during the last quarter. Captrust Financial Advisors purchased a new stake in shares of NeoGenomics during the second quarter valued at $66,000. Nisa Investment Advisors LLC grew its holdings in shares of NeoGenomics by 867.5% during the third quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock valued at $74,000 after buying an additional 3,470 shares during the last quarter. Winslow Evans & Crocker Inc. purchased a new stake in shares of NeoGenomics during the second quarter valued at $92,000. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in shares of NeoGenomics by 75.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock valued at $87,000 after buying an additional 1,950 shares during the last quarter. 85.02% of the stock is currently owned by institutional investors and hedge funds.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: How to Invest in a Bull Market
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.